Abstract

The Contractor shall perform clinical evaluations of treatment regimens utilizing activated leukocytes sponsored by the Division of Cancer Treatment, NCI, under an investigational new drug application (IND). Specifically, the Contractor shall: 1) determine the antitumor activity of activating agents in combination with activated leukocytes in a variety of human cancers in patients with advanced disease and minimal prior therapy; 2) define the toxicities of activating agents administered in combination with activated leukocytes to patients with advanced cancer; 3) evaluate new methods for activation of leukocytes and determine the antitumor activity of activated leukocytes generated using the new methodology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM073703-002
Application #
3614789
Study Section
Project Start
1987-06-30
Project End
1991-06-29
Budget Start
1988-06-30
Budget End
1989-06-29
Support Year
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010

  Publications

Atkins, M B; Lotze, M T; Dutcher, J P et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-16
Hawkins, M J; Atkins, M B; Dutcher, J P et al. (1994) A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol 15:74-8
Sparano, J A; Fisher, R I; Weiss, G R et al. (1994) Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother Emphasis Tumor Immunol 16:216-23
Sparano, J A; Fisher, R I; Sunderland, M et al. (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-77
Weiss, G R; Margolin, K A; Aronson, F R et al. (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10:275-81
Margolin, K A; Aronson, F R; Sznol, M et al. (1991) Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. J Immunother (1991) 10:214-20
Dutcher, J P; Gaynor, E R; Boldt, D H et al. (1991) A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9:641-8
Parkinson, D R; Fisher, R I; Rayner, A A et al. (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8:1630-6
Parkinson, D R; Abrams, J S; Wiernik, P H et al. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 8:1650-6
Sznol, M; Mier, J W; Sparano, J et al. (1990) A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. J Biol Response Mod 9:529-37

Showing the most recent 10 out of 12 publications